MDT

87.57

-0.57%↓

120.59

-0.17%↓

VEEV

167.81

+7.03%↑

HQY

83.41

+4.13%↑

NEOG

9.53

+0.21%↑

MDT

87.57

-0.57%↓

120.59

-0.17%↓

VEEV

167.81

+7.03%↑

HQY

83.41

+4.13%↑

NEOG

9.53

+0.21%↑

MDT

87.57

-0.57%↓

120.59

-0.17%↓

VEEV

167.81

+7.03%↑

HQY

83.41

+4.13%↑

NEOG

9.53

+0.21%↑

MDT

87.57

-0.57%↓

120.59

-0.17%↓

VEEV

167.81

+7.03%↑

HQY

83.41

+4.13%↑

NEOG

9.53

+0.21%↑

MDT

87.57

-0.57%↓

120.59

-0.17%↓

VEEV

167.81

+7.03%↑

HQY

83.41

+4.13%↑

NEOG

9.53

+0.21%↑

Kodu・Aktsiate loetelu・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Avatud

SektorTervishoid

1.81 3.43

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.73

Max

1.81

Põhinäitajad
By Trading Economics
Sissetulek	-2.8M -16M
Müük	-8.7M 5.5M
Kasumimarginaal	-282.723
Töötajad	81
EBITDA	-4.2M -15M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+123.98% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	12. mai 2026

Turustatistika
By TradingEconomics
Turukapital	73M 724M
Eelmine avamishind	-1.62
Eelmine sulgemishind	1.81

Uudiste sentiment

By Acuity

41%

59%

127 / 348 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

0.6863 / 0.72 Toetus ja vastupanu

Lexicon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

14. apr 2026, 23:36 UTC

Omandamised, ülevõtmised, äriostud

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion -- Update

14. apr 2026, 23:24 UTC

Kuumad aktsiad

Stocks to Watch: Gloo, Broadcom, GitLab

14. apr 2026, 22:42 UTC

Omandamised, ülevõtmised, äriostud

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion

14. apr 2026, 21:32 UTC

Suurimad hinnamuutused turgudel

GitLab Shares Rise on Expanded Google Cloud Collaboration

14. apr 2026, 23:54 UTC

Market Talk

Nikkei May Rise as Fears About Energy Shortage Ease -- Market Talk

14. apr 2026, 23:34 UTC

Market Talk

Gold Edges Lower on Possible Technical Correction -- Market Talk

14. apr 2026, 22:54 UTC

Tulu

BRP: Amendment Mainly Leads to 25% Tariff on Total Value of Imported Snowmobiles and Majority of ORV Models, Replacing Previous 50% Tariff on Applicable Metal Content Only >DOO.T

14. apr 2026, 22:54 UTC

Tulu

BRP: Suspending Guidance Following Amendment of Section 232 Tariffs on Steel, Aluminum and Copper Imports Into U.S., Which Came Into Effect on April 6 >DOO.T

14. apr 2026, 22:54 UTC

Tulu

BRP: Currently Estimates Potential Incremental Tariff Cost Related to This Amendment in Excess of $500M for Remainder of Yr >DOO.T

14. apr 2026, 22:54 UTC

Tulu

BRP: Suspends FY27 Guidance Due to Changes to U.S. Tariff Environment

14. apr 2026, 22:17 UTC

Omandamised, ülevõtmised, äriostud

Yancoal Australia: Targets Deal Completion Toward End of 3Q

14. apr 2026, 22:17 UTC

Omandamised, ülevõtmised, äriostud

Yancoal Australia: Acquisition Diversifies Portfolio; Met Coal Share to Rise to 22%

14. apr 2026, 22:17 UTC

Omandamised, ülevõtmised, äriostud

Yancoal Australia: Asset 'Strong Strategic Fit'; to Positively Add Production, Cash Flow

14. apr 2026, 22:16 UTC

Omandamised, ülevõtmised, äriostud

Yancoal Australia: Intends to Fund Acquisition With Cash, 5-Year Loan Facility

14. apr 2026, 22:15 UTC

Omandamised, ülevõtmised, äriostud

Yancoal Australia: Contingent Consideration Linked to Average Annual Prices For 5 Years

14. apr 2026, 22:14 UTC

Omandamised, ülevõtmised, äriostud

Yancoal Australia: Deal Includes Contingent Cash Consideration Up to $550 Million

14. apr 2026, 22:13 UTC

Omandamised, ülevõtmised, äriostud

Yancoal Australia: Deal Includes $1.85 Billion Upfront Consideration

14. apr 2026, 22:12 UTC

Omandamised, ülevõtmised, äriostud

Yancoal Australia: To Buy Kestrel Stake From EMR Capital, Adaro Capital

14. apr 2026, 22:12 UTC

Omandamised, ülevõtmised, äriostud

Yancoal Australia: To Buy Kestrel Stake For Up to $2.4 Billion

14. apr 2026, 22:10 UTC

Omandamised, ülevõtmised, äriostud

Yancoal Australia: to Acquire 80% Interest in Kestrel Coal Mine

14. apr 2026, 20:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Basic Materials Roundup: Market Talk

14. apr 2026, 20:33 UTC

Omandamised, ülevõtmised, äriostud

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

14. apr 2026, 20:32 UTC

Kuumad aktsiad

Stocks to Watch: JPMorgan, American Airlines, LVMH, BlackRock -- WSJ

14. apr 2026, 19:59 UTC

Omandamised, ülevõtmised, äriostud

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

14. apr 2026, 19:38 UTC

Tulu

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14. apr 2026, 19:27 UTC

Market Talk

U.S. Natural Gas Futures Extend Losing Streak -- Market Talk

14. apr 2026, 19:21 UTC

Market Talk

Uudisväärsed sündmused

Oil Futures Retreat on Hopes for U.S.-Iran Peace Talks -- Market Talk

14. apr 2026, 19:09 UTC

Omandamised, ülevõtmised, äriostud

Apple and Amazon Partner on Satellite Deal. Why It Makes Sense. -- Barrons.com

14. apr 2026, 18:30 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14. apr 2026, 18:30 UTC

Market Talk

Treasury Yields, Dollar Fall as Markets Price Higher Odds of Fed Cuts -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Lexicon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

123.98% tõus

12 kuu keskmine prognoos

Keskmine 3.83 USD 123.98%

Kõrge 6 USD

Madal 1 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Lexicon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Lexicon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.6863 / 0.72Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentiment

By Acuity

127 / 348 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.